Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jimmy Giang

Gastroenterology Greeley, CO Doctor of Osteopathy

NPI 1073933941 CMS profile 4222107

8225 W 20Th St, Greeley, CO 80634

Open in the dashboard

General payments

$8,116

340 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jimmy Giang of Greeley, CO is reported in the CMS Open Payments database as having received $8,116 across 340 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,003 84
2024 General $2,322 103
2023 General $1,555 83
2022 General $477 18
2021 General $685 27
2020 General $331 11
2019 General $742 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jimmy Giang
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jimmy Giang were reported at $2,003. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jimmy Giang Gastroenterology median Middle half National median
2019 $742 $417 $126–$1,100 $163
2020 $331 $224 $74–$624 $114
2021 $685 $352 $106–$1,054 $132
2022 $477 $448 $129–$1,270 $149
2023 $1,555 $533 $150–$1,390 $160
2024 $2,322 $605 $160–$1,606 $164
2025 $2,003 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,141 103 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $987 40 payments
  3. Janssen Biotech, Inc. $732 34 payments
  4. Gilead Sciences, Inc. $724 28 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $508 26 payments
  6. Regeneron Healthcare Solutions, Inc. $394 13 payments
  7. Genzyme Corporation $334 14 payments
  8. Intercept Pharmaceuticals, Inc. $292 5 payments
  9. Ardelyx, Inc. $227 8 payments
  10. Pfizer Inc. $222 7 payments
  11. Other $1,555 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,044 339 payments
  2. Gift $72 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $843 43 payments
  2. ENTYVIO $664 28 payments
  3. STELARA $451 22 payments
  4. XIFAXAN $451 22 payments
  5. LINZESS $434 21 payments
  6. MAVYRET $420 23 payments
  7. DUPIXENT $334 14 payments
  8. SKYRIZI $328 21 payments
  9. HUMIRA $288 9 payments
  10. TREMFYA $280 12 payments
  11. Other $3,963 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,041

Median for Gastroenterology: 569

Drug cost

$51,494

Median for Gastroenterology: $104,976

Branded share of claims

53.2%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 20 $16,233
Mesalamine Generic 12 $14,979
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 128 $8,613
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 246 $3,823
Omeprazole Generic 243 $3,207
Famotidine Generic 115 $1,590
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 44 $960
Pantoprazole Sodium Generic 41 $442
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 23 $437
Dicyclomine Hcl Generic 20 $409

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$122,170

Medicare's payments for the services billed

Medicare patients

398

Average age 72

Services billed

2,111

199 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 46%
Diabetes 26%
Ischemic heart disease 26%
Depression 23%
Chronic kidney disease 22%
Cancer 17%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $138
  • GENZYME CORPORATION $117
$255 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $206
$206 — —
RINVOQ
  • AbbVie, Inc. $192
$192 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $166
$166 — —
IBSRELA
  • Ardelyx, Inc. $147
$147 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

340 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record